The purpose of this study is to collect existing tissue specimens from subjects enrolled in Vasculitis Clinical Research Consortium (VCRC) studies. Analysis of these tissue specimens and linked clinical data collected through VCRC studies may lead to the identification and development of a series of translational research projects. Results of these studies will provide vasculitis researchers with insight into the causes of these diseases and generate new ideas for diagnostic tests and therapies, and will be of great interest to the larger communities of researchers investigating vasculitis and other autoimmune, inflammatory, and vascular diseases.
A participant will be deemed eligible for this study if the participant is/was enrolled in another one of the VCRC observational/longitudinal protocols (5502, 5503, 5504, 5505, 5506, 5507, 5563) and/or one of the VCRC interventional studies (5522, 5523, 5526, 5527, or 5562).
Inability to give informed consent (or their guardians in the case of children) and to sign the consent form.
Unwilling to allow the use of their tissue for research.
A total of 1000 patients with GCA, TAK, PAN, GPA, MPA, EGPA, cutaneous vasculitis and aortitis will potentially be enrolled into the VCRC Tissue Biorepository Collection Protocol. The protocol will be conducted at the major vasculitis centers in the United States and Canada participating in selected VCRC studies. Biopsy specimens collected as standard of care for these diseases will be retrieved and used in research. Biopsies are not performed as part of this protocol, rather we will request consent to collect biopsy specimens already collected under routine care.
Cohort
Other
Not listed
Identify genes that increase the risk of developing vasculitis
Evaluating of clinical data and linked biopsy specimens to identify genes that increase the risk of developing vasculitis.
Click on the lead sponsor to view all of their trials.
University of Pennsylvania
Lead sponsor
National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS)
Collaborator
National Center for Advancing Translational Sciences (NCATS)
Collaborator
Office of Rare Diseases (ORD)
Collaborator
